Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorvotuzumab mertansine

Next Previous
X
Search
Drug Profile

Lorvotuzumab mertansine

Alternative Names: BB-10901; huN901-DM1; huN901-DM1 antibody; huN901-SPP-DM1; IMGN-901; IMGN901 TAP; Monoclonal antibody huN901-DM1 conjugate

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD56 antigen inhibitors; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Merkel cell carcinoma; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple myeloma; Solid tumours
  • Discontinued Haematological malignancies; Small cell lung cancer

Most Recent Events

  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 09 Apr 2021 Discontinued - Phase-II for Haematological malignancies in USA (IV) (NCT02420873)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma in Argentina (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top